Our Harbour Mice^® antibody technology platforms are supported by a comprehensive suite of in-house technology tools, including but not limited to single B cell cloning, next-generation sequencing, immunizations, bioinformatics, protein science, yeast/phage/mammalian display libraries, antibody engineering and artificial intelligence.

Moreover, our HBICE^® bispecific technology enables us to generate flexible formats to accommodate different mechanisms of action. Our mammalian direct cloning platform allows for highly efficient bispecific antibody screening, surpassing traditional methods.

We hold exclusive global rights to use and develop our Harbour antibody platforms, which are protected by a robust portfolio of global patents. This intellectual property position enables us to maximize the platform’s value in addressing unmet medical needs worldwide.

These achievements demonstrate our discovery team’s expertise and technical prowess in translating target biology into points of innovation and differentiation. Driven by an experienced group of over 100 scientists with extensive research and drug development experience, our operations in the United States, China, and the Netherlands are advancing our mission:

To Be the Leading Company Driving Global Innovation of Next-Generation Antibody Therapeutics.